Highlights

• IAG shares declined after the ACCC rejected the proposed RAC Insurance acquisition.
• The regulator flagged potentially high Western Australian market concentration across home and motor insurance.
• IAG will pursue a public-benefit application, with the next regulatory phase expected to take about 50 business days.

Regulatory Setback Pressures IAG Shares

Insurance Australia Group Limited (ASX: IAG) faced downward share-price pressure after the ACCC declined to approve its planned purchase of RAC Insurance. IAG was trading at a CMP of AU$7.940, down 1.61%, as investors assessed the regulatory setback and the additional uncertainty surrounding the transaction.

The immediate pressure on IAG shares appears linked to the ACCC's Phase 2 determination, which prevents the proposed transaction from proceeding in its current form. The regulator determined that the proposed deal could materially weaken competition across Western Australia’s motor and home insurance markets.

Why Did IAG Shares Decline?

The decline reflects increased uncertainty over whether IAG can ultimately complete its planned RAC Insurance transaction. The ACCC's decision introduces another regulatory hurdle, extends the transaction timetable and reduces near-term visibility over the strategic benefits IAG expected from expanding its Western Australian insurance presence.

Competition concerns are particularly significant because both businesses already have meaningful positions in the state. RAC Insurance holds a leading position in Western Australia’s motor and home insurance markets, where IAG also maintains a significant competitive presence.

Market Concentration Raises Concerns

The scale of the combined business was central to the ACCC's assessment. The regulator estimated that, if completed, the transaction could give IAG about 55%–65% of Western Australia’s motor insurance market and around 50%–60% of the state’s home and contents insurance market.

The ACCC also determined that IAG and RAC Insurance are effective competitors and indicated that IAG could become a stronger competitor independently if the acquisition does not proceed.

IAG Is Not Abandoning the Transaction

Despite the adverse Phase 2 outcome, the proposed alliance has not reached the end of the regulatory process. IAG confirmed that it intends to lodge a public-benefit application, allowing the transaction to be assessed on broader customer, community and economic benefits alongside competition considerations.

IAG expects this next stage to take approximately 50 business days. Management argues that the proposed partnership could deliver benefits through IAG's technology platforms, claims-management capabilities, financial strength and global reinsurance protection.

Regulatory Battle Has Already Been Lengthy

The latest decision follows an earlier regulatory challenge. IAG initially sought clearance under Australia's previous informal merger framework, but the ACCC opposed the acquisition in December 2025. IAG subsequently notified the transaction under the formal merger regime introduced on 1 January 2026.

This history helps explain the market's cautious reaction: the transaction now faces another review period rather than providing shareholders with near-term certainty.

IAG's Core Business Remains Substantial

Importantly, the regulatory decision relates to the proposed RAC transaction rather than IAG's existing insurance operations. IAG remains a major Australia-New Zealand general insurance group, with its principal businesses underwriting more than AU$18 billion of insurance premiums annually across brands including NRMA Insurance, RACV, RACQI, CGU, WFI, NZI, State, AMI and Lumley.

What Could Drive IAG From Here?

From an equity-research perspective, the 1.61% decline to AU$7.940 is consistent with investors pricing in higher execution and regulatory uncertainty following the ACCC decision, rather than evidence in the supplied releases of deterioration in IAG's underlying insurance operations.

Attention now shifts to the public-benefit assessment. A favourable determination could revive the proposed alliance, while another adverse outcome would force investors to reassess IAG's Western Australian growth strategy without the RAC Insurance transaction. Until that process advances, regulatory developments are likely to remain an important near-term catalyst.

Note- All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au